Revolution Medicines' Experimental Drug Doubles Survival in Early Pancreatic Cancer Trials
Researchers report that Revolution Medicines' experimental drug, daraxonrasib, significantly extends survival in early pancreatic cancer patients. This breakthrough offers hope in a field where prognosis has been traditionally grim, and further testing is underway to validate these findings.
· 44d ago
